Brain Reward History

Click Here For Abstracts
  • 2012
  • Journal of Psychoactive Drugs

    Early Intervention of Intravenous KB220IV- Neuroadaptagen Amino-Acid Therapy (NAAT)™ Improves Behavioral Outcomes in a Residential Addiction Treatment Program: A Pilot Study

    December issue 2012).
  • Cross over triple–blind–placebo controlled study

    Neurotransmitter-precursor-supplement Intervention for Detoxified Heroin Addicts.

    Early 2012
  • 2011
  • “Dopamine Resistance” in brain reward circuitry

    “Dopamine Resistance” in brain reward circuitry as a function of DRD2 gene receptor polymorphisms in RDS: Synaptamine complex variant (KB220) induced “Dopamine Sensitivity” and enhancement of happiness.

    2011
  • 2010
  • Overcoming qEEG abnormalities and reward gene deficits

    Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine Dâ‚‚ agonist therapy: part 2.

    2010
  • Acute intravenous synaptamine complex variant KB220™

    Acute intravenous synaptamine complex variant KB220™ "normalizes" neurological dysregulation in patients during protracted abstinence from alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis for reward polymorphisms: part 1, pilot study with 2 case reports.

    2010
  • Sustainable Weight Loss and Muscle Gain

    Sustainable Weight Loss and Muscle Gain Utilizing the Rainbow Diet™: Targeting Noradrenergic and dopaminergic Mechanistic Sites, Hormonal Deficiency Repletion Therapy and Exercise: A case report.

    2010
  • 2009
  • Putative targeting of Dopamine

    Putative targeting of Dopamine D2 receptor function in Reward Deficiency Syndrome (RDS) by Synaptamine Complex™ Variant (KB220): Clinical trial showing anti-anxiety effects.

    2009
  • 2008
  • Dopamine D2 Receptor Taq A1

    Putative targeting of Dopamine D2 receptor function in Reward Deficiency Syndrome (RDS) by Synaptamine Complex™ Variant (KB220): Clinical trial showing anti-anxiety effects.

    2008
  • LG839: anti-obesity effects

    LG839: anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome.

    2008
  • 2007
  • Efficacy and safety of LG839

    A short term pilot open label study to evaluate efficacy and safety of LG839, a customized DNA directed nutraceutical in obesity: Exploring Nutrigenomics.

    2007
  • Nutrient Induces Changes In Body

    Chromium Picolinate (Crp) A putative Anti-Obesity Nutrient Induces Changes In Body Composition As Function Of The Taq1 Dopamine D2 Receptor Gene.

    2007
  • Research Extends to 1973